Cardiomyopathy Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults who have been diagnosed with a heart condition called arrhythmogenic cardiomyopathy (ACM), based on a specific set of recognised medical guidelines from 2010.
• People who have a confirmed genetic change in a gene called PKP2 that is known or likely to cause disease.
• People who experience frequent irregular heartbeats originating from the lower chambers of the heart (called premature ventricular contractions, or PVCs).
• People who already have an implanted defibrillator device (ICD) before entering the trial.
• For Part A of the trial: people whose heart's pumping function (left ventricular ejection fraction) is measured at 50% or above. For Part B: people whose heart's pumping function is measured at 40% or above.

Who may not be able to join:

• People who have an additional genetic change in another gene that is also considered to cause or likely cause an arrhythmogenic heart condition.
• People with a history of certain other heart abnormalities as detailed in the trial's protocol (confirm with trial site).
• People who are experiencing the most severe level of heart failure symptoms (classified as New York Heart Association Class IV) at the time of joining the trial.
• People who have previously received any form of gene therapy treatment.

Important: Always verify eligibility with the trial site directly before applying.